The GSK ValueHealth Patient Program (VHPP) continues its strong commitment to improve patient access to quality medicine and adherence to treatment regimen prescribed by healthcare professionals. The VHPP provides program benefits for each participating brand, with patients at the heart of everything we do.

Here are the brands that are part of VHPP

-Co-Amoxiclav - Augmentin®

-Fluticasone Furoate - Avamys®

-Levocetirizine - Xyzal®

-Cefuroxime Axetil - Zinnat®

-Acyclovir - Zovirax ®

-Salmeterol Plus Fluticasone Propionate - Seretide®

-Fluticasone Furoate Plus Vilanterol Trifenatate - Relvar ®

-Umeclidinium Bromide Plus Vilanterol Trifenatate - Anoro®

-Levetiracetam - Keppra®

-Lamotrigine  - Lamictal®

-Lacidipine - Lacipil®

Click here to see the specific program benefits per brand

Kindly forward all adverse events and product complaints to GSK Philippines via these contact details:
Adverse Event: ph.safety@gsk.com or 09178890640
Product Complaint: 09178897050     PH/MARK/0026/16 December 2016